Skip to main content
. 2021 Apr 9;12(4):549. doi: 10.3390/genes12040549

Figure 3.

Figure 3

Interactions among different drug combinations for TNBC therapy with significantly upregulated miRNAs (red), downregulated miRNAs (orange), and their target genes (green) for: (A) platinum compounds, alkylating agents, cisplatin, and carboplatin; (B) cisplatin, doxorubicin, and cyclophosphamide; (C) paclitaxel, docetaxel, carboplatin, cyclophosphamide, doxorubicin, and 5-flourouracil (5-FU); (D) doxorubicin, paclitaxel, and cyclophosphamide.